Sivelestat
Chemical compound
- None
- US: Not approved
- In general: ℞ (Prescription only)
- N-{2-[({4-[(2,2-dimethylpropanoyl)oxy]phenyl}sulfonyl)amino]benzoyl}glycine
- 127373-66-4 N
- 107706
- 6441
- 96875 Y
- DWI62G0P59
- D03788 Y
- ChEMBL76688 Y
- DTXSID9048304
- Interactive image
- CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC(=O)O
InChI
- InChI=1S/C20H22N2O7S/c1-20(2,3)19(26)29-13-8-10-14(11-9-13)30(27,28)22-16-7-5-4-6-15(16)18(25)21-12-17(23)24/h4-11,22H,12H2,1-3H3,(H,21,25)(H,23,24) Y
- Key:BTGNGJJLZOIYID-UHFFFAOYSA-N Y
Sivelestat (INN, research name ONO 5046, marketed as Elaspol) is an inhibitor of human neutrophil elastase.[1]
It is used in the treatment of acute respiratory failure[2] and preliminary studies show it may also improve neuropathic pain.[3]
Synthesis
Sivelestat is synthesised as follows:[4]
References
- ^ Kawabata K, Suzuki M, Sugitani M, Imaki K, Toda M, Miyamoto T (June 1991). "ONO-5046, a novel inhibitor of human neutrophil elastase". Biochemical and Biophysical Research Communications. 177 (2): 814–820. doi:10.1016/0006-291X(91)91862-7. PMID 2049103.
- ^ Imokawa S, Mori K, Harada M, Sagisaka S, Sano T, Uchiyama H, et al. (June 2008). "[Acute respiratory failure due to pneumocystis pneumonia successfully treated with combined use of sivelestat sodium hydrate]". Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society (in Japanese). 46 (6): 461–465. PMID 18592991.
- ^ Weyer AD, Stucky CL (May 2015). "Repurposing a leukocyte elastase inhibitor for neuropathic pain". Nature Medicine. 21 (5): 429–430. doi:10.1038/nm.3861. PMID 25951529. S2CID 10240018.
- ^ US 5017610, Imaki K, Arai Y, Okegawa T, "Derivatives of p-substituted phenyl ester of pivalic acid", issued 21 May 1991, assigned to Ono Pharmaceutical Co Ltd
- v
- t
- e